8 completed, 3 terminated, 2 recruiting, 1 active not recruiting. 14 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 8, Terminated 3, Recruiting 2, Active not recruiting 1 |
| Phase 1 | 3 | Completed 1, Recruiting 1, Terminated 1 |
Follow Anaplastic Oligodendroglioma: new trials by email Literature Review of Anaplastic Oligodendroglioma trials Research Report on Anaplastic Oligodendroglioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas Biospecimen Collection, Eflornithine, Lumbar Puncture - Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 33 | 2026-06-23 | 2026-06-24 |
| Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy - Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2020-01-30 | 2026-07-16 |
| Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma Biospecimen Collection, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 2 | Active not recruiting | NRG Oncology | 120 | 2018-01-23 | 2026-07-28 |
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors Dabrafenib, trametinib, Carboplatin - Diffuse Astrocytoma, Anaplastic Astrocytoma | Phase 2 | Completed | Novartis Pharmaceuticals | 151 | 2017-12-28 | 2023-12-13 |
| Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Temozolomide - Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma | Phase 2 | Completed | Seoul National University Hospital | 23 | 2013-05-01 | 2016-04-26 |
| Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas AXL1717 - Glioblastoma, Gliosarcoma | Phase 1 / Phase 2 | Terminated | Rush University Medical Center | 10 | 2012-12-01 | 2023-05-22 |
| BIBF 1120 for Recurrent High-Grade Gliomas BIBF 1120 - Glioblastoma, Gliosarcoma | Phase 2 | Completed | Patrick Y. Wen, MD | 37 | 2012-05-01 | 2014-08-18 |
| A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas ZD6474 (Vandetanib), Carboplatin - Glioblastoma Multiforme, Gliosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 112 | 2009-09-01 | 2016-03-29 |
| Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma ritonavir, lopinavir - Brain Tumor, Anaplastic Astrocytoma | Phase 2 | Terminated | Case Comprehensive Cancer Center | 19 | 2009-01-01 | 2013-06-10 |
| Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Bevacizumab, MLN-518 (Tandutinib), Quality-of-life assessment - Glioblastoma, Gliosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 42 | 2008-04-01 | 2015-11-05 |
| Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors Carboplatin, Etoposide, Etoposide Phosphate - Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma | Phase 1 / Phase 2 | Completed | OHSU Knight Cancer Institute | 33 | 2005-09-15 | 2022-03-17 |
| Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Temozolomide - Oligoastrocytoma, Mixed, Anaplastic Oligodendroglioma | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 1 | 2005-05-01 | 2017-11-30 |
| Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas Talampanel - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 2 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 30 | 2003-07-01 | 2011-05-23 |
| Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms carmustine, mercaptopurine, streptozocin - Anaplastic Astrocytoma, Anaplastic Oligodendroglioma | Phase 2 | Completed | Emory University | 35 | 1996-08-01 | 2015-03-25 |
Oligodendroglioma (14) · Astrocytoma (13) · Glioblastoma (10) · Glioma (8) · Brain Neoplasms (5) · Gliosarcoma (5) · Ependymoma (2) · Disease Progression (1) · Ganglioglioma (1) · Ganglioneuroma (1) · Genetic Diseases, Inborn (1) · Lymphoma, Follicular (1) · Neurocytoma (1) · Rare Diseases (1) · Recurrence (1)
Neoplasms (14) · Neoplasms by Histologic Type (14) · Neoplasms, Germ Cell and Embryonal (14) · Neoplasms, Glandular and Epithelial (14) · Neoplasms, Nerve Tissue (14) · Neoplasms, Neuroepithelial (14) · Neuroectodermal Tumors (14) · Brain Diseases (6) · Central Nervous System Diseases (6) · Central Nervous System Neoplasms (6) · Glioma (6) · Neoplasms by Site (6) · Nervous System Diseases (6) · Nervous System Neoplasms (6) · Disease Attributes (3)
Temozolomide (4) · Carboplatin (3) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Bevacizumab (1) · Carmustine (1) · Eflornithine (1) · Etoposide (1) · Lopinavir (1) · Mannitol (1) · Melphalan (1) · Mercaptopurine (1) · Proton Therapy (1) · Protons (1) · Quality of Life (1)
National Cancer Institute (NCI) (2) · Case Comprehensive Cancer Center (1) · Emory University (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · NRG Oncology (1) · Novartis Pharmaceuticals (1) · OHSU Knight Cancer Institute (1) · Ohio State University Comprehensive Cancer Center (1) · Patrick Y. Wen, MD (1) · Rush University Medical Center (1) · Seoul National University Hospital (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1)
United States (11) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1)
David Peereboom, MD (1) · David R Grosshans (1) · Debra N Yeboa (1) · Edward A Neuwelt (1) · Herbert Newton, MD (1) · Howard Fine, M.D. (1) · Katherine E Warren, M.D. (1) · Mark R. Gilbert (1) · Patrick Y Wen, M.D. (1) · Robert Aiken, MD (1) · Tae Min Kim, MD, PhD (1) · Terence C. Burns, MD, PhD (1)
PMID 21242491, PMID 25098701, PMID 25338318, PMID 26860632, PMID 34331515, PMID 37610803, PMID 37643378, PMID 37733309, PMID 41740060
2015 (1), U10CA180868 (1)